insights_auto
Kwa nini HELP imepungua kwa 2.39%?
Fahamu zaidichevron_right
HELP:NASDAQ
Cybin Inc
US$ 11.42
arrow_downward
-2.39%(-0.28) Siku 1
US$ 11.42
0.00% (0.00)
bedtimeBaada ya saa
Imefungwa: 5 Okt, 16:00:01 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya HELP...
Fungua
US$ 11.50
Juu
US$ 11.74
Chini
US$ 11.23
Wastani wa kiasi cha mauzo
1.72M
Kiasi cha mauzo ya hisa
1.31M
Juu kwa wiki 52
US$ 15.15
Chini kwa wiki 52
US$ 3.76
Beta
0.53
Hisa za wawekezaji
73.06M
Idadi ya wafanyakazi
100
Fungua
US$ 11.50
Juu
US$ 11.74
Chini
US$ 11.23
Wastani wa kiasi cha mauzo
1.72M
Kiasi cha mauzo ya hisa
1.31M
Juu kwa wiki 52
US$ 15.15
Chini kwa wiki 52
US$ 3.76
Beta
0.53
Hisa za wawekezaji
73.06M
Idadi ya wafanyakazi
100
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
TipRanks
·
saa 4 zilizopita
Helus Pharma Files October Form 6-K and Corporate Amendment with U.S. SEC
Wasifu
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Kuhusu Cybin Inc
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi100
Lilianzishwa2019
Makao makuuToronto, Ontario, Kanada
Sekta-
Tovutihelus.com